ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease
February 22, 2022 08:00 ET
|
Immix Biopharma, Inc.
IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cellsImmixBio anticipates filing an IND for IMX-120 in 2023The...
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022
February 01, 2022 09:30 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics...
ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data
January 31, 2022 08:00 ET
|
Immix Biopharma, Inc.
Manufactured IMX-110 to be utilized in both clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned combination IMX-110 + BeiGene anti-PD-1...
IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale
January 25, 2022 10:15 ET
|
Immix Biopharma, Inc.
IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune systemHistorically,...
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles
January 19, 2022 08:00 ET
|
Immix Biopharma, Inc.
100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trialIMX-110 is in clinical development as a monotherapy...
ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study
January 12, 2022 08:00 ET
|
Immix Biopharma, Inc.
IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mice studyIMX-110 response rate surpassed standard...
Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders
January 06, 2022 09:00 ET
|
Immix Biopharma, Inc.
Los Angeles, CA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM...
U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children
January 03, 2022 08:00 ET
|
Immix Biopharma, Inc.
Rare Pediatric Disease Designation (“RPDD”) qualifies Immix Biopharma to receive fast track review, and a priority review voucher (“PRV”) at the time of marketing approval of IMX-110.PRV holders can...
Immix Biopharma, Inc. Announces Closing of Initial Public Offering
December 20, 2021 16:16 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM...
Immix Biopharma, Inc. Announces Pricing of Initial Public Offering
December 15, 2021 18:00 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM...